v3.25.1

Total revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Total revenues |
Revenue by collaboration and by category of revenue | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Over time |  | Point in time | ​ | 2024 |  | ​ | 2023 | ​ | ​ | 2022
​ | ​ | ​ | ​ | ​ | ​ | (Euro, in | ​ | ​ | (Euro, in | ​ | ​ | (Euro, in
​ | ​ | ​ | ​ | ​ | ​ | thousands) | ​ | ​ | thousands) | ​ | ​ | thousands)
Recognition of non-refundable upfront payments and license fees | ​ | ​ | ​ | ​ | ​ | € | 230,182 | ​ | € | 230,242 | ​ | € | 230,423
Gilead collaboration agreement for drug discovery platform | ​ | Ö | ​ | ​ | ​ | ​ | 230,182 | ​ | ​ | 230,242 | ​ | ​ | 230,423
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reimbursement income | ​ | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 56
Novartis collaboration agreement for MOR106 | ​ | Ö | ​ | ​ | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 56
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Royalties | ​ | ​ | ​ | ​ | ​ | ​ | 10,604 | ​ | ​ | 9,482 | ​ | ​ | 10,770
Gilead royalties on Jyseleca | ​ | ​ | ​ | Ö | ​ | ​ | 10,604 | ​ | ​ | 9,466 | ​ | ​ | 10,726
Other royalties | ​ | ​ | ​ | Ö | ​ | ​ | — | ​ | ​ | 16 | ​ | ​ | 44
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total collaboration revenues | ​ | ​ | ​ | ​ | ​ | € | 240,786 | ​ | € | 239,724 | ​ | € | 241,249

X
- Definition n/a + References No definition available. + Details
Name: | glpg_DisclosureOfTotalRevenuesAndOtherIncomeAbstract
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue by collaboration and by category of revenue. + References No definition available. + Details
Name: | glpg_SummaryOfRevenuesByCollaborationAndByCategoryOfRevenueTableTextBlock
Namespace Prefix: | glpg_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration